Fig 2: Influence of human and mouse Cometin and EPO on neuronal morphology after 48 h of incubation. SGN were distinguished into monopolar (A,B), bipolar (C,D) and neurons without neurites (E,F) after treatment with Cometin (A,C,E) or EPO (B,D,F). No relevant differences were detected between treatment conditions. Independent experiments: 3, wells per experiment: 3.

Fig 3: SGN survival rate after treatment with mouse and human Cometin (A) or EPO (B). No factor-application served as negative control (NC) and 10 ng/mL BDNF served as a positive control (PC). BDNF increased neuronal survival in both test series significantly. 10 µg/mL human Cometin significantly increased the SGN survival rate compared to the NC and all other Cometin conditions and did not differ from PC. In contrast, the addition of 10 ng/mL human EPO significantly decreased SGN survival compared to NC, PC, and the other EPO conditions. No other treatment affected the SGN survival rate significantly compared to the NC. While 10 µg/mL human Cometin significantly improved SGN survival compared to the same concentration of mouse Cometin and the lower human concentrations, the opposite was the case for EPO. Here the 10 ng/mL of human EPO significantly reduced the SGN survival compared to the mouse EPO of the same concentration and the tested lower human concentrations. Asterisks above the error bars indicate the significant differences between the marked experimental conditions and the respective group indicated by the arrowhead. *p < 0.05, **p < 0.01, ***p < 0.001; independent experiments: 3; wells per experiment: 3.